Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Passage Bio, Inc./ S-4/A

Business Combination Registration · S-4/A

Passage Bio, Inc.

PASGNASDAQEQUITYCurrent

Business Combination Registration

Filed Sep 21, 2026Accepted Sep 21, 2026, 5:30 PM EDTCIK 1787297Accession 0001140361-26-037256
View company →Permanent SEC source ↗
Share

Company context

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Passage Bio’s primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression.

Current securities

PASGNASDAQ · EQUITY · Current

Recent company filings

  1. S-4/A filingSep 3, 2026
  2. 425 filingSep 3, 2026
  3. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 3, 2026
  4. SCHEDULE 13G/A filingAug 14, 2026
  5. 10-Q filingAug 10, 2026

As-filed source

Primary evidence
As filedOpen full document ↗